Patents by Inventor William B. Parker
William B. Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220031817Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Applicants: The UAB Research Foundation, Southern Research InstituteInventors: William B. Parker, Eric J. Sorscher
-
Publication number: 20180360929Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.Type: ApplicationFiled: August 10, 2018Publication date: December 20, 2018Inventors: William B. Parker, Eric J. Sorscher
-
Patent number: 10080784Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.Type: GrantFiled: February 20, 2012Date of Patent: September 25, 2018Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATIONInventors: William B. Parker, Eric J. Sorscher
-
Publication number: 20160022784Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).Type: ApplicationFiled: July 16, 2015Publication date: January 28, 2016Inventors: Steven E. EALICK, William B. PARKER, Eric J. SORSCHER
-
Publication number: 20140199285Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).Type: ApplicationFiled: January 14, 2014Publication date: July 17, 2014Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATIONInventors: William B. Parker, Eric J. Sorscher
-
Patent number: 8628767Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).Type: GrantFiled: August 17, 2009Date of Patent: January 14, 2014Assignees: The UAB Research Foundation, Southern Research InstituteInventors: William B. Parker, Eric J. Sorscher
-
Publication number: 20130330315Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.Type: ApplicationFiled: February 20, 2012Publication date: December 12, 2013Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATIONInventors: William B. Parker, Eric J. Sorscher
-
Publication number: 20110218170Abstract: Compounds represented by the formulae: wherein R is individually selected from the group consisting of H, aliphatic acyl, aromatic acyl group, fluoro, chloro, bromo, iodo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano, aryl and nitro; pharmaceutically acceptable salts thereof, prodrugs thereof, solvates thereof and mixtures thereof; are used as inhibitors of DNA methyltransferase and for treating patients suffering from diseases resulting from or related to aberrant DNA methylation such as myelodysplastic syndromes and other cancers.Type: ApplicationFiled: March 2, 2010Publication date: September 8, 2011Applicant: Southern Research InstituteInventors: Jaideep Thottassery, Kamal N. Tiwari, William B. Parker, John A. Secrist, III
-
Publication number: 20110212073Abstract: A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(?-D-arabinofuranosyl)-2-fluoroadenine (F-araA).Type: ApplicationFiled: August 17, 2009Publication date: September 1, 2011Applicants: THE UAB RESEARCH FOUNDATIONInventors: William B. Parker, Eric J. Sorscher
-
Publication number: 20100151572Abstract: Described are methods and compositions for inhibiting undesired cells by expression of one or more exogenous enzymes in the cells and administration of a prodrug which is a substrate for at least one of the enzymes to produce a cytotoxic compound. Inventive methods and compositions are active to inhibit cells expressing the exogenous enzymes as well as bystander cells. Tumor cells are a particular target for inhibition using methods and compositions detailed according to the present invention. Provided are methods and compositions for improved anti-tumoral effects by overexpression of adenine phosphoribosyltransferase (APRT) to produce cytotoxins which inhibit the cells overexpressing the APRT as well as bystander cells. Overexpression of APRT in conjunction with expression of E. coli PNP and administration of a substrate for E. coli PNP provides particularly effective anti-tumoral effects.Type: ApplicationFiled: May 16, 2006Publication date: June 17, 2010Inventors: Eric J. Sorscher, William B. Parker, Jeong S. Hong
-
Publication number: 20100129317Abstract: Azole nucleosides represented by the formulae (I) and (II); wherein A=C or N B?C or N X?H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br and I; OH, NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); Z?H; C1-C6 alkyl, cycloalkyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, I; OH NH2, NH—(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo; E=(CH2)HONHR; n is an interger from 0-6 and more typically 0-3; R1= aryl or heterocyclo; each of W, Y, R is individually selected from the group consisting of H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, and I; O, OH, Oalkyl, Oaryl, NH2, NH(C1-C6 alkyl, cycloalkyl, aryl or heterocyclo); provided that at least one of W, Y, and R is other than H and wherein both W and Y together can be ?O; and each D individually is OH, Oalkyl, Oaryl, FL and H; pharmaceutically acceptable salts thereof, prodrugs thereof and mixtures thereof are provided.Type: ApplicationFiled: September 11, 2007Publication date: May 27, 2010Applicant: SOUTHERN RESEARCH INSTITUTEInventors: Jeffrey B. Arterburn, Colleen B. Jonsson, William B. Parker
-
Patent number: 7488598Abstract: A host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside cleavage enzymes is provided. The transformed or transfected host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. A nucleotide sequence encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth is also provided. A method is detailed for the delivery of toxin by generation within target cells or by administration and delivery to the cells from without. Novel purine nucleosides are detailed that yield a cytotoxic purine upon enzymatic cleavage. A synthetic process for nucleosides is also detailed.Type: GrantFiled: October 28, 2002Date of Patent: February 10, 2009Assignees: Cornell Center for Technology Enterprise and Commercialization, The UAB Research Foundation, Southern Research InstituteInventors: Steven E. Ealick, William B. Parker, John A. Secrist, III, Eric J. Sorscher
-
Patent number: 7048079Abstract: A three-part sub-assembly comprising a wire line retrievable spear. The spear having two fluid chambers. A diverter valve having a truncated, inverted cone valve seat is preferably threaded into the interior of the spear. A diverter valve stem, having back-to-back cones is located within the interior of the spear/diverter valve combination, with one of the cones having a linear extension which prevents the first cone from completely seating against the valve seat within the interior of the spear. The spear/diverter valve assembly and a spring-loaded piston is placed within the interior of the cylinder and utilizes an adjustable ring within the interior of the cylinder as an adjustment for varying mud weights.Type: GrantFiled: July 11, 2002Date of Patent: May 23, 2006Assignee: Mud Saver, Inc.Inventor: William B. Parker
-
Patent number: 7037718Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.Type: GrantFiled: October 26, 2001Date of Patent: May 2, 2006Assignees: Cornell Research Foundation, Inc., Southern Research Institute, The UAB Research FoundationInventors: Steven E. Ealick, William B. Parker, John A. Secrist, III, Eric J. Sorscher
-
Patent number: 6958318Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.Type: GrantFiled: July 18, 2002Date of Patent: October 25, 2005Assignees: The UAB Research Foundation, Southern Research InstituteInventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett, Jr.
-
Publication number: 20040204375Abstract: Compounds having the structure: 1Type: ApplicationFiled: November 3, 2003Publication date: October 14, 2004Inventors: Eric J Sorscher, Jeong S Hong, Jennifer E Harris, Kimberly V Curlee, Joseph A Maddry, William B Parker, William R Wand
-
Publication number: 20030228576Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for mutant purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells. The present invention provides nucleotide sequences encoding mutant E. coli derived purine nucleoside phosphorylase proteins which can be used in conjunction with an appropriate substrate to produce toxins which impair abnormal cell growth. The invention provides for delivery of the toxin by generation within target cells or by administration and delivery to the cells from without.Type: ApplicationFiled: October 26, 2001Publication date: December 11, 2003Inventors: Steven E. Ealick, William B. Parker, John A. Secrist, Eric J. Sorscher
-
Publication number: 20030134819Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.Type: ApplicationFiled: July 18, 2002Publication date: July 17, 2003Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett
-
Publication number: 20030077268Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.Type: ApplicationFiled: July 18, 2002Publication date: April 24, 2003Inventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett
-
Patent number: 6491905Abstract: The present invention provides a procaryotic host cell stably transformed or transfected by a vector including a DNA sequence encoding for purine nucleoside phosphorylase or hydrolase. The transformed or transfected procaryotic host cell can be used in combination with a purine substrate to treat tumor cells and/or virally infected cells.Type: GrantFiled: October 30, 1998Date of Patent: December 10, 2002Assignees: The UAB Research Foundation, Southern Research InstituteInventors: Eric J. Sorscher, William B. Parker, William Waud, Vijayakrishna K. Gadi, Leonard L. Bennett, Jr.